Publication

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi, W
; 
Jiang, T
; 
Nuciforo, P
; 
Hatzis, C
; 
Holmes, E
; 
Harbeck, N
; 
Sotiriou, C
; 
Peña, L
; 
Loi, S
; 
Rosa, D
... show 10 more
Citations
Altmetric:
Abstract
We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival.
Authors
Shi, W
Jiang, T
Nuciforo, P
Hatzis, C
Holmes, E
Harbeck, N
Sotiriou, C
Peña, L
Loi, S
Rosa, D
Chia, S
Wardley, Andrew M
Ueno, T
Rossari, J
Eidtmann, H
Armour, A
Piccart-Gebhart, M
Rimm, D
Baselga, J
Pusztai, L
Affiliation
Yale University, Yale Cancer Center, New Haven CT;Yale University, Yale Cancer Center, New Haven CT
Description
Date
2016-09-29
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. 2016, Ann Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/619976
Embedded videos